drugset / Trial / NCT01336660
A Trial of Equine F (ab')2 Antivenom for Treatment of Scorpion Envenomation in Morocco
Phase 2/3
Completed
56 enrolled
Instituto Bioclon S.A. de C.V.
Centre Antipoison et de Pharmacovigilane du Maroc · collabInstitut Pasteur du Maroc · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study has the objective to demonstrate the effectiveness of Alacramyn NAMO in the treatment of North Africa and Middle East scorpions envenomation by reducing the severity of envenomation. The primary endpoint is make a comparison between antivenom and placebo groups, at 4 hours after study drug, of the number of cases showing improvement in class of envenomation.
Timeline
- Start
- 2018-07-21
- Primary completion
- 2018-11-01
- Completion
- 2018-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Equine F(ab')2 antivenom | Protein / enzyme biologic | 4 unknown | Intravenous |